251 related articles for article (PubMed ID: 17991725)
1. Proteolytic cleavage of human chromogranin a containing naturally occurring catestatin variants: differential processing at catestatin region by plasmin.
Biswas N; Vaingankar SM; Mahata M; Das M; Gayen JR; Taupenot L; Torpey JW; O'Connor DT; Mahata SK
Endocrinology; 2008 Feb; 149(2):749-57. PubMed ID: 17991725
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides.
Biswas N; Rodriguez-Flores JL; Courel M; Gayen JR; Vaingankar SM; Mahata M; Torpey JW; Taupenot L; O'Connor DT; Mahata SK
Endocrinology; 2009 Aug; 150(8):3547-57. PubMed ID: 19372204
[TBL] [Abstract][Full Text] [Related]
3. Catecholamine release-inhibitory peptide catestatin (chromogranin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension.
Rao F; Wen G; Gayen JR; Das M; Vaingankar SM; Rana BK; Mahata M; Kennedy BP; Salem RM; Stridsberg M; Abel K; Smith DW; Eskin E; Schork NJ; Hamilton BA; Ziegler MG; Mahata SK; O'Connor DT
Circulation; 2007 May; 115(17):2271-81. PubMed ID: 17438154
[TBL] [Abstract][Full Text] [Related]
4. The catecholamine release-inhibitory "catestatin" fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nicotinic cholinergic responses.
Mahata SK; Mahata M; Wen G; Wong WB; Mahapatra NR; Hamilton BA; O'Connor DT
Mol Pharmacol; 2004 Nov; 66(5):1180-91. PubMed ID: 15326220
[TBL] [Abstract][Full Text] [Related]
5. Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release.
Jiang Q; Taupenot L; Mahata SK; Mahata M; O'Connor DT; Miles LA; Parmer RJ
J Biol Chem; 2001 Jul; 276(27):25022-9. PubMed ID: 11342539
[TBL] [Abstract][Full Text] [Related]
6. The chromogranin A fragment catestatin: specificity, potency and mechanism to inhibit exocytotic secretion of multiple catecholamine storage vesicle co-transmitters.
Mahapatra NR; Mahata M; Mahata SK; O'Connor DT
J Hypertens; 2006 May; 24(5):895-904. PubMed ID: 16612252
[TBL] [Abstract][Full Text] [Related]
7. Primary sequence characterization of catestatin intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin a into active catestatin secreted from neuroendocrine chromaffin cells.
Lee JC; Taylor CV; Gaucher SP; Toneff T; Taupenot L; Yasothornsrikul S; Mahata SK; Sei C; Parmer RJ; Neveu JM; Lane WS; Gibson BW; O'Connor DT; Hook VY
Biochemistry; 2003 Jun; 42(23):6938-46. PubMed ID: 12795588
[TBL] [Abstract][Full Text] [Related]
8. Functional genetic variants of the catecholamine-release-inhibitory peptide catestatin in an Indian population: allele-specific effects on metabolic traits.
Sahu BS; Obbineni JM; Sahu G; Allu PK; Subramanian L; Sonawane PJ; Singh PK; Sasi BK; Senapati S; Maji SK; Bera AK; Gomathi BS; Mullasari AS; Mahapatra NR
J Biol Chem; 2012 Dec; 287(52):43840-52. PubMed ID: 23105094
[TBL] [Abstract][Full Text] [Related]
9. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines.
Aung G; Niyonsaba F; Ushio H; Kajiwara N; Saito H; Ikeda S; Ogawa H; Okumura K
Immunology; 2011 Apr; 132(4):527-39. PubMed ID: 21214543
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action of chromogranin A on catecholamine release: molecular modeling of the catestatin region reveals a beta-strand/loop/beta-strand structure secured by hydrophobic interactions and predictive of activity.
Tsigelny I; Mahata SK; Taupenot L; Preece NE; Mahata M; Khan I; Parmer RJ; O'Connor DT
Regul Pept; 1998 Oct; 77(1-3):43-53. PubMed ID: 9809795
[TBL] [Abstract][Full Text] [Related]
11. Heritability and genome-wide linkage in US and australian twins identify novel genomic regions controlling chromogranin a: implications for secretion and blood pressure.
O'Connor DT; Zhu G; Rao F; Taupenot L; Fung MM; Das M; Mahata SK; Mahata M; Wang L; Zhang K; Greenwood TA; Shih PA; Cockburn MG; Ziegler MG; Stridsberg M; Martin NG; Whitfield JB
Circulation; 2008 Jul; 118(3):247-57. PubMed ID: 18591442
[TBL] [Abstract][Full Text] [Related]
12. Analysis and validation of traits associated with a single nucleotide polymorphism Gly364Ser in catestatin using humanized chromogranin A mouse models.
Mir SA; Zhang K; Milic M; Gu Y; Rieg T; Ziegler M; Vaingankar SM
J Hypertens; 2016 Jan; 34(1):68-78. PubMed ID: 26556564
[TBL] [Abstract][Full Text] [Related]
13. Monocyte migration: a novel effect and signaling pathways of catestatin.
Egger M; Beer AG; Theurl M; Schgoer W; Hotter B; Tatarczyk T; Vasiljevic D; Frauscher S; Marksteiner J; Patsch JR; Schratzberger P; Djanani AM; Mahata SK; Kirchmair R
Eur J Pharmacol; 2008 Nov; 598(1-3):104-11. PubMed ID: 18834877
[TBL] [Abstract][Full Text] [Related]
14. Catestatin is a novel endogenous peptide that regulates cardiac function and blood pressure.
Mahapatra NR
Cardiovasc Res; 2008 Dec; 80(3):330-8. PubMed ID: 18541522
[TBL] [Abstract][Full Text] [Related]
15. Processing of chromogranin A by plasmin provides a novel mechanism for regulating catecholamine secretion.
Parmer RJ; Mahata M; Gong Y; Mahata SK; Jiang Q; O'Connor DT; Xi XP; Miles LA
J Clin Invest; 2000 Oct; 106(7):907-15. PubMed ID: 11018079
[TBL] [Abstract][Full Text] [Related]
16. Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway.
Kiranmayi M; Chirasani VR; Allu PK; Subramanian L; Martelli EE; Sahu BS; Vishnuprabu D; Kumaragurubaran R; Sharma S; Bodhini D; Dixit M; Munirajan AK; Khullar M; Radha V; Mohan V; Mullasari AS; Naga Prasad SV; Senapati S; Mahapatra NR
Hypertension; 2016 Aug; 68(2):334-47. PubMed ID: 27324226
[TBL] [Abstract][Full Text] [Related]
17. Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.
Mahata SK; Mahata M; Wakade AR; O'Connor DT
Mol Endocrinol; 2000 Oct; 14(10):1525-35. PubMed ID: 11043569
[TBL] [Abstract][Full Text] [Related]
18. Conformational preferences and activities of peptides from the catecholamine release-inhibitory (catestatin) region of chromogranin A.
Preece NE; Nguyen M; Mahata M; Mahata SK; Mahapatra NR; Tsigelny I; O'Connor DT
Regul Pept; 2004 Apr; 118(1-2):75-87. PubMed ID: 14759560
[TBL] [Abstract][Full Text] [Related]
19. Formation of the catecholamine release-inhibitory peptide catestatin from chromogranin A. Determination of proteolytic cleavage sites in hormone storage granules.
Taylor CV; Taupenot L; Mahata SK; Mahata M; Wu H; Yasothornsrikul S; Toneff T; Caporale C; Jiang Q; Parmer RJ; Hook VY; O'Connor DT
J Biol Chem; 2000 Jul; 275(30):22905-15. PubMed ID: 10781584
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A: a novel susceptibility gene for essential hypertension.
Sahu BS; Sonawane PJ; Mahapatra NR
Cell Mol Life Sci; 2010 Mar; 67(6):861-74. PubMed ID: 19943077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
